Close Menu

NEW YORK ─ RenalytixAI on Monday said that it has set the terms for its previously announced US initial public offering, saying the estimated net proceeds from the sale of 11,000,000 shares, including those represented by American Depositary Shares (ADSs) in the offering, will be approximately $69.9 million after deducting estimated underwriting discounts and commissions and other offering expenses.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.